Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Nivolumab and Paricalcitol in Resectable Pancreatic Cancer
NCT03519308Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paricalcitol and nivolumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Adverse Events at 18 months. Started Jul 2020; status: terminated.
02
Drugs
paricalcitolnivolumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03519308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519308.